Mark A. Nelson, PhD

Professor, Pathology
  • Washington State University, Pharmacology/Toxicology (Ph.D.)
  • University of Arizona, Molecular Carcinogenesis (Postdoctoral Fellow)
Honors and Awards: 
  • First award, R29 (NIH)
  • Richard C. Deauveaurant Outstanding Young Investigator, Cancer Research Foundation of America
Major Areas of Research Interest: 

Molecular mechanisms of physical and chemical carcinogenesis; biochemical and molecular pharmacology of cancer chemopreventative drugs; human tumorigenesis (specifically melanoma) and mechanisms of cancer chemopreventive agents.

Selected Publications: 
Nelson MA. Reynolds SH. Rao UN. Goulet AC. Feng Y. Beas A. Honchak B. Averill J. Lowry DT. Senft JR. Jefferson AM. Johnson RC. Sargent LM. Increased gene copy number of the transcription factor E2F1 in malignant melanoma. Cancer Biology & Therapy. 5(4):407-12, 2006.
Shi J. Kahle A. Hershey JW. Honchak BM. Warneke JA. Leong SP. Nelson MA. Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene. 25(35):4923-36, 2006.
Hoff SJ. Bundy DS. Nelson MA. Zelle BC. Jacobson LD. Heber AJ. Ni J. Zhang Y. Koziel JA. Beasley DB. Emissions of ammonia, hydrogen sulfide, and odor before, during, and after slurry removal from a deep-pit swine finisher. Journal of the Air & Waste Management Association. 56(5):581-90, 2006.
Nelson MA. Goulet AC. Jacobs ET. Lance P. Studies into the anticancer effects of selenomethionine against human colon cancer. Annals of the New York Academy of Sciences. 1059:26-32, 2005.
Sponsored Research Through MSRP: 

Cynthia Burk (MSRP 2001): "COX-2 Expression in Melanoma"

Wednesday, November 18, 2015